Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon explained up to 86% of the variance in glucagon-like peptide 1, whereas cortisol explained up to 89% of the variance in interleukin 6 in hyperglycemia after AP.
|
31091214 |
2020 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The SCI-hyperglycemia-curcumin group showed a statistically significant reduction in IL-6, IL-8, and TNF-α levels compared with the SCI-hyperglycemia group after SCI.
|
31421247 |
2019 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Insulin also significantly inhibited T1DM-induced hyperglycemia (p < 0.001), dyslipidemia (p < 0.0001), malondialdehyde (MDA; p < 0.0001), tumor necrosis factor-alpha (TNF-α; p < 0.001) and interleukin-6 (p < 0.001).
|
31185481 |
2019 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The intervention also suppressed serum monocyte chemotactic protein-1 and interleukin-6 levels, which are proinflammatory cytokines involved in the development of insulin resistance and hyperglycemia.
|
30502681 |
2019 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
More interestingly, BDNF inhibited hyperglycemia-induced microglial activation and reduced elevated levels of inflammatory factors (TNF-α, IL-6).
|
31165005 |
2019 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interleukin 6 Function in the Skin and Isolated Keratinocytes Is Modulated by Hyperglycemia.
|
31073533 |
2019 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<i>In vitro</i> experiments in rat macrophages showed that hyperglycemia treatment suppresses Nrf2 activation, resulting in oxidative stress with decreased expression of antioxidant genes, including NAD(P)H:quinone oxidoreductase 1 and heme oxygenase 1, together with increased secretion of proinflammatory cytokines, including interleukin 1β (IL1β), IL6, and monocyte chemoattractant protein-1.
|
31616304 |
2019 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The untreated diabetic group showed hyperglycemia and increased diuresis, creatinine clearance, proteinuria, glycosuria and urinary excretion of <i>N</i>-acetyl-β-d-glucosaminidase (NAG), as well as increased oxidative stress and the expression of interleukin 1β (IL-1β), IL-6, nuclear factor kappa beta (NFκβ) and transforming growth factor-β1 (TGF-β1) in plasma and kidney.
|
30314265 |
2018 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings provide evidence that a single bout of exhaustive exercise protects against acute olanzapine-induced hyperglycemia and that IL-6 is neither sufficient, nor required for exercise to protect against increases in blood glucose with olanzapine treatment.
|
29335597 |
2018 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, compared with control group the expression of IL1R1 and IL-6 genes both were downregulated in individuals with moderately high blood glucose levels by 2.38 (p = 0.0365) and 4.34 fold (p = 0.0027), respectively.
|
29851525 |
2018 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The hyperglycemia can directly promote an inflammatory state where the increase C-reactive (CRP) and cytokines, such as interleukins (IL-1 and IL-6), which contribute to the development of cardiovascular diseases.
|
28939513 |
2018 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pre-adipocytes and adipocytes in this state secrete pro-inflammatory adipokines, such as interleukin 6 (IL-6), which induce insulin resistance and hyperglycemia.
|
29625124 |
2018 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Expression of macrophage genes within skeletal muscle correlates inversely with adiposity and insulin resistance in humans.
|
29035695 |
2018 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Streptozotocin (STZ)-induced type 2 DM is used as a model of human type 2 DM in which peripheral insulin resistance, increased plasma interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and hyperglycemia occurs.
|
29309791 |
2018 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In summary, our observations demonstrate that the activation of either IL-6 classic or trans-signalling advances podocyte harming under hyperglycaemia.
|
28881473 |
2018 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Gene expression studies were performed for muscle (GLUT4) and liver tissues (IL6 and PAI1).There was a remarkable decrease in hyperglycemia within two weeks of injection by MetASCs as compared to metformin and ASCs alone.
|
27842906 |
2016 |
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multiple logistic analysis showed that IL6 -174CC genotype carriers had increased risk for hyperglycemia (>5.77 mmol/l) [OR: 6.75, 95 % CI: 1.80-24.40, p = 0.004] and hypertriglyceridemia (>2.68 mmol/l) [OR: 3.00, 95 % CI: 1.00-9.00, p = 0.043].
|
23135962 |
2013 |
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-6 polymorphisms are associated with obesity and hyperglycemia in Mexican adolescents.
|
23142265 |
2013 |
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We determined the associations between esophagectomy-induced stress hyperglycemia (> or =30 mg/dl increases in blood glucose during surgery) and genetic polymorphisms for C-reactive protein (CRP), tumor necrosis factor (TNF)-alpha, -beta, interferon-gamma, transforming growth factor-beta1, interleukin (IL)-1beta, IL-2, IL-4, IL-6, IL-6 receptors, IL-10, IL-12beta, adiponectin, and peroxisome proliferator-activated receptor-gamma.
|
20145925 |
2010 |
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Possession of the IL-6 rs1800797 GG genotype by the LTA and TNF-alpha risk genotype carriers further increased risk of the MetS [OR 2.10 (CI 1.19-3.71) P = 0.009], fasting hyperglycemia [OR 2.65 (CI 1.12-6.28), P = 0.027], high systolic blood pressure [OR 1.99 (CI 1.07-3.72), P = 0.03], and abdominal obesity [OR 1.52 (CI 1.01-2.28), P = 0.04].
|
20080841 |
2010 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
LHGDN |
Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus.
|
18211631 |
2008 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Secreted IL-6, intracellular IL-6, and IL-6 mRNA were significantly increased with hyperglycemia (P < 0.001).
|
15616014 |
2005 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Secreted IL-6, intracellular IL-6, and IL-6 mRNA were significantly increased with hyperglycemia (P < 0.001).
|
15616014 |
2005 |
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High levels of IL-6 are associated with hyperglycaemia, dyslipidemia and provoke insulin resistance.
|
16518702 |
2005 |
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|